Compare RCEL & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCEL | MTLS |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.3M | 431.6M |
| IPO Year | 2018 | 2014 |
| Metric | RCEL | MTLS |
|---|---|---|
| Price | $16.88 | $6.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $13.26 | $9.99 |
| AVG Volume (30 Days) | ★ 429.2K | 245.3K |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.20 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $71,610,000.00 | N/A |
| Revenue This Year | $24.33 | $3.97 |
| Revenue Next Year | $26.85 | $5.95 |
| P/E Ratio | ★ N/A | $61.39 |
| Revenue Growth | ★ 11.45 | N/A |
| 52 Week Low | $3.22 | $4.78 |
| 52 Week High | $16.90 | $8.82 |
| Indicator | RCEL | MTLS |
|---|---|---|
| Relative Strength Index (RSI) | 67.16 | 33.64 |
| Support Level | $3.86 | $6.37 |
| Resistance Level | $16.90 | $6.94 |
| Average True Range (ATR) | 1.15 | 0.41 |
| MACD | -0.03 | -0.17 |
| Stochastic Oscillator | 70.61 | 15.84 |
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.